[1] | Avwioro, O.G., 2002, Histochemistry and tissue pathology principles and techniques, 1st ed. Claverianum Publishers, Ibadan, Nigeria. Pp: 293-296. |
[2] | Shabnam, J., and Ira, J.B., 2004, Beyond Hematoxylin and Eosin. The Role of Immunohistochemistry in Surgical Pathology. Cancer invest. 22 (3): 445–465. |
[3] | Ramos-Vara, J.A., and Miller, M.A., 2014, When tissue antigens and antibodies get along: the technical aspects of Immunohistochemistry. Vet. Pathol. 51: 42-87. |
[4] | Molinie, V., Fromont, G., Sibony, M., Vieillefond, A., Vassiliu, V., Cochand-Priollet, B., et al., 2004, Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod. Path. 17:1180-1190. |
[5] | Taylor, C.R., and Levenson, R.M., 2006, Quantification of Immunohistochemistry–issues concerning methods, utility and semiquantitative assessment. Histopathol. 49: 411-424. |
[6] | Van der Loos, C.M., 2008, Multiple immunoenzyme staining: methods and visualizations for the observation with spectral imaging. J. Histochem. Cytochem. 56:313-328. |
[7] | Van der Loos, C.M., Immunoenzyme Multiple Staining Methods: BIOS Scientific Ltd.; 1999. |
[8] | Chaubert, P., Bertholet, M.M., Correvon, M., Laurini, S., and Bosman, F.T., 1997, Simultaneous double immunoenzymatic labeling: a new procedure for the histopathologic routine. Mod Path. 10: 585-591. |
[9] | Pileri, S.R., Roncandor, G., and Ceccarelli, C., 1997, Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J. Pathol. 183:116–123. |
[10] | Chan, J.K.C., 1998, Advances in immunohistochemical techniques: toward making things simpler, cheaper, more sensitive and more reproducible. Adv. Anat. Pathol. 5: 314–325. |
[11] | Werner, M., Chott, A., and Fabiano, A., 2000, Effect of formalin tissue fixation and processing of immunohistochemistry. Am. J. Surg. Pathol. 24:1016–1019. |
[12] | Diest van, P.J., Dam van, P., and Henzen-Longmans, S.J., 1997, A scoring system for immunohistochemical staining: consensus report for basic research of the EORTC-GCCG. J. Clin. Pathol. 50: 801–804. |
[13] | Mighell, A.J., Hume, W.J., and Robinson, P.A.,1998, An overview of the complexities and subtleties of immunohistochemistry. Oral Dis. 4: 217–223. |
[14] | Biesterfeld, S., Veuskens, U., and Schmitz, F.J., 1996, Interobserver reproducibility of immunocytochemical estrogen and progesterone receptor status assessment in breast cancer. Anticancer Res. 16: 2497–2500. |
[15] | Press, M.F., Pike, M.C., and Chazin, V.R., 1993, Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53: 4960–4970. |
[16] | Hall, P.A., Hughes, C.M., and Staddon S.L. (1990). The c-erbB-2 protooncogene in human pancreatic cancer. J. Pathol. 161: 195– 200. |
[17] | Zhau, H.E., Zhang, X., and Von Eschenbach, A., 1990, Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog. 3: 254–257. |
[18] | Field, J.K., Spandidos, D.A., and Yiagnisis, M., 1992, C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res. 12: 613–620. |
[19] | Sheibani, K., Shin, S.S., and Kezirian, J., 1991, Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma vs adenocarcinoma. Am. J. Surg. Pathol. 15: 779–784. |
[20] | Riera, J.R., Astengo-Osuna, C., and Longmate, J.A. (1997). The Immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation following heat-induced epitope retrieval. Am. Surg. Pathol. 21:1409–1419. |
[21] | Gaffey, M.J., Mills, S.E., Swanson, P.E., et al., 1992, Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am. J. Surg. Pathol. 16: 593–599. |
[22] | Latza, U., Niedobitek, G., and Schwarting, R., 1990, Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelia. J. Clin. Pathol. 43: 213–219. |
[23] | Allred, D.C., Harvey, J.M., Berardo, M., 1998, Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathol. 11:155–168. |
[24] | Battifora, H., Mehta, P., and Ahn, C., 1993, Estrogen receptor Immunohistochemical assay in paraffin-embedded tissue: a better gold standard? Appl Immunohistochem.1: 39–45. |
[25] | Battifora, H., Esteban, J.M., and Bacus, S., 1990, Quantitative immunocytochemistry on paraffin-embedded tissues: the Quicgel method. Lab Invest. 62: 8. |
[26] | Riera, J.R., Simpson, J.F., and Tamayo, R., 1999, Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer: the Quicgel method. Am. J. Clin. Pathol. 111: 329–335. |
[27] | Chu, P., Wu, E., and Weiss, L.M., 2000, Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 13:962–72. |
[28] | Coindre, J.M., 2003, Immunohistochemistry in the diagnosis of soft tissue tumours. Histopathol. 43: 1–16. |
[29] | Barak, V., Goike, H., and Panaretakis, K.W., 2004, Clinical utility of cytokeratins as tumor markers. Clin. Biochem. 37:529–540. |
[30] | Chu, P.G., and Weiss, L.M., 2002, Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol. 15:6–10. |
[31] | Higgins, R.A., Blankenship, J.E., and Kinney, M.C., 2008. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch. Pathol. Lab. Med. 132:441–61. |
[32] | Cho, R.J., McCalmont, T.H., and Ai, W.Z., 2012, Use of an expanded Immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators. J Cutan Pathol. 39:651–658. |
[33] | McCourt, C.M., Boyle, D., James, J., and Salto-Tellez, M., 2013, Immunohistochemistry in the era of personalized Medicine. J. Clin. Pathol. 66: 58–61. |
[34] | Vasen, H.F., 2005, Clinical description of the Lynch syndrome hereditary nonpolyposis colorectal cancer (HNPCC). Fam Cancer. 4: 219–225. |
[35] | Poulogiannis, G., Frayling, I.M., and Arends, M.J., 2010, DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathol. 56: 167–179. |
[36] | Umar, A., Boland, C.R., and Terdiman, J.P., 2004, Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 96: 261–268. |
[37] | Salto-Tellez, M., Lee, S.C., and Chiu, L.L., 2004, Microsatellite instability in colorectal cancer: considerations for molecular diagnosis and high-throughput screening of archival tissues. Clin. Chem. 50:1082–1086. |
[38] | Pertschuk, L.P., Feldman, J.G., Kim, Y.D., Braithwaite, L., Schneider, F., Braverman, A.S., and Axiotis, C., 1996, Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H22SP2 ligand binding assays. Cancer. 77: 2514–2519. |
[39] | Harvey, J.M., Clark, G.M., Osborne, C.K., and Allred, D.C., 1999, Estrogen receptor status by Immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17: 1474–1481. |
[40] | Chan, J.K.C., 2000, Advances in immunohistochemistry. Impact on surgical pathology practice. Sem. Diagn. Pathol. 17(3): 17–77. |